Autres langues X4 Pharmaceuticals, Inc.

Actions

XFOR

US98420X1037

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 26/04/2024			Pré-ouverture 13:06:18
1,165 ^USD	+3,10 %		1,31	+12,45 %

21/03	Transcript : X4 Pharmaceuticals, Inc., Q4 2023 Earnings Call, Mar 21, 2024
21/03	X4 Pharmaceuticals, Inc. annonce ses résultats pour le quatrième trimestre et l'exercice clos le 31 décembre 2023	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

X4 Pharmaceuticals Announces FDA Approval of XOLREMDI™ (mavorixafor) Capsules, First Drug Indicated in Patients with WHIM Syndrome	12:30
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)	03/04
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	02/04
X4 Pharmaceuticals : Regulation FD Disclosure - Form 8-K	01/04
X4 Pharmaceuticals to Participate in Upcoming April Investor Conferences	01/04
X4 Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	21/03
X4 Pharmaceuticals: Q4 Earnings Snapshot	21/03
North American Morning Briefing : Investors -2-	21/03
X4 Pharmaceuticals Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides Corporate Update	21/03
X4 Pharmaceuticals to Report Fourth-Quarter and Full Year 2023 Financial Results and Host a Conference Call and Webcast on March 21, 2024	12/03
Thinking about buying stock in Marpai, Axcelis Technologies, Amylyx Pharmaceuticals, Biomx, or X4 Pharmaceuticals?	11/03
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)	04/03
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	01/03
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	01/02
North American Morning Briefing : Traders Await -2-	13/12
X4 Pharmaceuticals Announces Presentation of Additional Data from Mavorixafor Phase 2 Trial in Chronic Neutropenia at ASH 2023	11/12
X4 Pharmaceuticals Announces Presentation of Additional Data from Mavorixafor Phase 2 Trial in Chronic Neutropenia at ASH 2023	09/12
X4 Pharmaceuticals, Inc. Announces Presentation of Additional Data from Mavorixafor Phase 2 Trial in Chronic Neutropenia at ASH 2023	09/12
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)	05/12
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	04/12

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues X4 Pharmaceuticals, Inc.

Actions

XFOR

US98420X1037

Autres langues

Filtres